Dexcom ( (DXCM) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Dexcom’s stock has experienced unusual movements due to a recent FDA warning letter concerning its manufacturing processes. Despite this, analysts remain confident, maintaining a bullish outlook. The company has assured that the warning will not affect its revenue target of $4.6 billion or its manufacturing capabilities, thanks to a new facility in Malaysia. Dexcom is addressing the issues, which are related to processes and documentation rather than patient safety, indicating manageable solutions. The strategic expansion and the appointment of Renée Galá to the Board of Directors further support the company’s growth in the metabolic health sector, leading analysts to uphold strong buy ratings and a positive long-term outlook.
More about Dexcom
YTD Price Performance: -9.91%
Average Trading Volume: 3,715,449
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $27.64B
For further insights into DXCM stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.
Questions or Comments about the article? Write to editor@tipranks.com